Elsevier

Critical Care Clinics

Volume 26, Issue 1, January 2010, Pages 151-179
Critical Care Clinics

Acute Kidney Injury in Critically Ill Patients with Cancer

https://doi.org/10.1016/j.ccc.2009.09.002Get rights and content

Section snippets

Definition and early identification of acute kidney injury

A major limitation to the correct interpretation of data on the epidemiology of AKI is the use of different definitions for AKI. At least 35 different definitions for AKI are used in the medical literature,45, 46 ranging from minor derangement of kidney function to severe AKI, such as AKI defined by the need for treatment with RRT. Comparison of incidence and outcome data of studies on AKI are hampered by this abundance of definitions. The RIFLE classification (Risk of renal dysfunction, Injury

Epidemiology of acute kidney injury in critically ill cancer patients

The incidence and hospital mortality associated with RRT in the general critically ill cancer population and the most important subgroups are depicted in detail in Tables 1 and 2, respectively. These tables include studies from 1990 onwards, focusing exclusively on cancer patients admitted to the ICU with life-threatening complications and for whom sufficient data were available.5, 6, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,

Causes of acute renal failure in critically ill cancer patients

AKI usually results from a combination of nephrotoxic insults in critically ill cancer patients, although a main insult is often identifiable in daily practice.6, 12, 13, 15 AKI may occur as a direct or indirect consequence of the cancer itself, its treatment, or associated complications. The most common causes of acute renal failure in cancer patients admitted to the ICU are listed in Table 3.6, 12, 13, 14, 15 Sepsis was the most common cause of AKI followed by nephrotoxic drugs. Dependent on

Sepsis

As in general ICU patients,49, 51, 52, 55 sepsis and, more particularly, severe sepsis and septic shock, is the most common main contributing factor to the development of AKI in critically ill cancer patients. Patients with hematologic malignancies, who often experience longer duration of neutropenia compared with solid tumor patients, are at particularly high risk of bacterial and, less frequently, fungal sepsis.2, 19, 20, 21, 25, 32, 37, 60 In a multicenter study comparing outcomes of cancer

Antimicrobial Drugs

Several antimicrobial drugs commonly used in the supportive care of febrile cancer patients and to those with severe sepsis and septic shock may induce AKI.14, 24

Aminoglycosides (gentamicin, tobramycin, amikacin) are commonly used in daily practice in cancer patients, although current guidelines no longer strictly recommend the use of aminoglycosides in combination with a β-lactam in febrile neutropenic patients.68 Also, 2 large meta-analyses, one performed in immunocompetent sepsis patients69

Tumor lysis syndrome

TLS is a metabolic disorder that results from the massive destruction of malignant cells and the subsequent abrupt release of intracellular anions (phosphate), cations (potassium), metabolic products of proteins, and nucleic acids (uric acid) into the extracellular space and the bloodstream.90, 91, 92 This rapid release may overwhelm the body's homeostatic mechanism to process and excrete these materials and result in the life-threatening clinical spectrum of TLS, which is characterized by AKI,

Diffuse Intravascular Coagulation

DIC is observed relatively frequently in cancer patients outside the setting of sepsis.93 The reported incidence is approximately 7% in solid tumor patients,94 increasing up to 10% to 15% in case of metastatic disease,93 to 15% to 20% in patients presenting with acute lymphoblastic leukemia, and to more than 90% in those with acute promyelocytic leukemia.93, 94 Darmon and colleagues14 reported that DIC was present in 26% of the cancer patients admitted to the ICU with AKI. Cancer-related DIC

Acute kidney injury secondary to ureteral obstruction

Ureteral obstruction is the fifth most common main or concomitant cause of AKI in cancer patients admitted to the ICU.14, 15 Ureteral obstruction carries an ominous prognosis, as it is usually observed in the context of extensive metastatic solid tumors often poorly responsive to chemotherapy. Median survival is only 3 to 7 months.118, 119, 120 Ureteral obstruction may result from a direct intrinsic or extrinsic compression of the ureters by a pelvic (bladder, prostate, cervix, ovaries) or

Multiple myeloma kidney

AKI is a common feature of multiple myeloma and often provides a clue to the diagnosis of this disease, particularly in the presence of a high serum total protein concentration in routine laboratory investigations. Only 52% of the multiple myeloma patients have normal renal function on presentation121, 122 and, depending on the definition, about 20% to 46% of de novo multiple myeloma patients present with AKI.122, 123, 124 Multiple myeloma represents about 3% of cancer patients30 and 10% to 21%

Who should benefit from advanced life-supportive therapy, including renal replacement therapy?

From the aforementioned data it should be clear that the presence of an underlying cancer alone can no longer be considered a contraindication to initiate RRT in critically ill patients. Moreover, long-term survival is no longer exceptional even in multiple organ failure cancer patients requiring RRT, at least in the context of septic shock outside the allogeneic hematopoietic transplant setting.12, 27 However, these relatively good results should not be used to warrant unrealistic therapeutic

Summary

Critically ill cancer patients have a higher incidence of AKI treated with RRT than critically ill patients without cancer. AKI may occur as a direct or indirect consequence of the cancer itself, its treatment, or associated complications. The presence of an underlying cancer alone can no longer be considered a contraindication to initiate RRT in critically ill patients. Moreover, recent studies have shown that long-term survival is no longer exceptional in multiple organ failure cancer

Acknowledgments

The authors would like to thank Pieter Depuydt, MD, PhD and Jean-Patrick Harvey, MD, respectively staff member and resident in training at the Department of Intensive Care of Ghent University Hospital Medical Unit, for reviewing the manuscript and for their useful comments.

First page preview

First page preview
Click to open first page preview

References (144)

  • P.T. Vaitkus et al.

    N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses

    Am Heart J

    (2007)
  • G. Marenzi et al.

    Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients

    Am J Med

    (2006)
  • I. Arany et al.

    Cisplatin nephrotoxicity

    Semin Nephrol

    (2003)
  • M.B. Davidson et al.

    Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

    Am J Med

    (2004)
  • M. Levi

    Disseminated intravascular coagulation in cancer patients

    Best Pract Res Clin Haematol

    (2009)
  • E. Stein et al.

    The coagulopathy of acute promyelocytic leukaemia revisited

    Best Pract Res Clin Haematol

    (2009)
  • W.R. Bell et al.

    Trousseau's syndrome. Devastating coagulopathy in the absence of heparin

    Am J Med

    (1985)
  • F.S. Taccone et al.

    First-ever stroke as initial presentation of systemic cancer

    J Stroke Cerebrovasc Dis

    (2008)
  • D.D. Benoit et al.

    Should we remain reluctant to admit critically ill cancer patients to the intensive care unit?

  • M. Darmon et al.

    Clinical review: specific aspects of acute renal failure in cancer patients

    Crit Care

    (2006)
  • F. Brunet et al.

    Is intensive care justified for patients with haematological malignancies?

    Intensive Care Med

    (1990)
  • J. Evison et al.

    Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors

    Swiss Med Wkly

    (2001)
  • J.J. Lanore et al.

    Hemodialysis for acute renal failure in patients with hematologic malignancies

    Crit Care Med

    (1991)
  • E. Azoulay et al.

    The intensive care support of patients with malignancy: do everything that can be done

    Intensive Care Med

    (2006)
  • F. Pène et al.

    Can we still refuse ICU admission of patients with hematological malignancies?

    Intensive Care Med

    (2008)
  • T. Silfvast et al.

    Multiple organ failure and outcome of critically ill patients with haematological malignancy

    Acta Anaesthesiol Scand

    (2003)
  • F. Kroschinsky et al.

    Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies

    Intensive Care Med

    (2002)
  • D.D. Benoit et al.

    Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies

    Nephrol Dial Transplant

    (2005)
  • T. Berghmans et al.

    Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience

    Support Care Cancer

    (2004)
  • M. Darmon et al.

    Should dialysis be offered to cancer patients with acute kidney injury?

    Intensive Care Med

    (2007)
  • M. Soares et al.

    Prognosis of critically ill patients with cancer and acute renal dysfunction

    J Clin Oncol

    (2006)
  • E. Azoulay et al.

    Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support

    Crit Care Med

    (2001)
  • E. Azoulay et al.

    Predictors of short-term mortality in critically ill patients with solid malignancies

    Intensive Care Med

    (2000)
  • E. Azoulay et al.

    Changing use of intensive care for hematological patients: the example of multiple myeloma

    Intensive Care Med

    (1999)
  • E. Azoulay et al.

    The prognosis of acute respiratory failure in critically ill cancer patients

    Medicine (Baltimore)

    (2004)
  • D.D. Benoit et al.

    Documented and clinically suspected bacterial infection precipitating intensive care unit admission in patients with hematological malignancies: impact on outcome

    Intensive Care Med

    (2005)
  • D.D. Benoit et al.

    Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication

    Crit Care Med

    (2003)
  • B. Lamia et al.

    Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU

    Intensive Care Med

    (2006)
  • J. Larchè et al.

    Improved survival of critically ill cancer patients with septic shock

    Intensive Care Med

    (2003)
  • V. Peigne et al.

    Continued survival gains in recent years among critically ill myeloma patients

    Intensive Care Med

    (2009)
  • F. Pène et al.

    Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit

    Crit Care Med

    (2008)
  • M. Soares et al.

    Effect of age on survival of critically ill patients with cancer

    Crit Care Med

    (2006)
  • M. Soares et al.

    Characteristics and outcomes of cancer patients requiring mechanical ventilatory support for >24 hrs

    Crit Care Med

    (2005)
  • M. Soares et al.

    Outcomes and prognostic factors in patients with head and neck cancer and severe acute illnesses

    Intensive Care Med

    (2007)
  • F.S. Taccone et al.

    Characteristics and outcomes of cancer patients in European ICUs

    Crit Care

    (2009)
  • L. Lecuyer et al.

    Case volume and mortality in haematological patients with acute respiratory failure

    Eur Respir J

    (2008)
  • T.M. Merz et al.

    Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study

    Crit Care

    (2008)
  • A.D. Cornet et al.

    Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care

    Eur J Haematol

    (2005)
  • D.M. Vandijck et al.

    Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies

    Intensive Care Med

    (2008)
  • D.D. Benoit et al.

    Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit

    Intensive Care Med

    (2006)
  • Cited by (48)

    • Conventional chemotherapy

      2019, Onco-Nephrology
    View all citing articles on Scopus
    View full text